Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Ltd (TATVA) last reported results for the quarter ended Jun 2026, with sales of ₹167 crore and net profit of ₹16 crore. The stock last traded at ₹1,843, a market capitalisation of ₹4,311 crore, on a P/E of 82.3. Over the past 52 weeks the stock has ranged between ₹1,022 and ₹1,880. Figures are as of 6 Oct 2026 and are not real time.
Tatva Chintan Pharma Chem Ltd share price and key metrics
- Current price
- ₹1,843
- Market cap
- ₹4,311 cr
- Stock P/E
- 82.3
- Book value
- ₹334
- ROE
- 5.54%
- ROCE
- 7.18%
- Dividend yield
- 0.11%
- 52w high / low
- 1880/1022
Metrics as of 6 Oct 2026. Not real time.
Track Tatva Chintan Pharma Chem Ltd
Cruxal reads every Tatva Chintan Pharma Chem Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Tatva Chintan Pharma Chem Ltd growth and returns
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 6%
- TTM
- 41%
- 10 Years
- %
- 5 Years
- -4%
- 3 Years
- -5%
- TTM
- 632%
- 10 Years
- %
- 5 Years
- -5%
- 3 Years
- 4%
- 1 Year
- 72%
- 10 Years
- %
- 5 Years
- 8%
- 3 Years
- 4%
- Last Year
- 6%
Tatva Chintan Pharma Chem Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹167 cr, up 42.7% from ₹117 cr a year earlier. Net profit was ₹16 cr, up 128.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 83 | 86 | 108 | 117 | 124 | 131 | 134 | 167 |
| Expenses | 78 | 79 | 99 | 100 | 101 | 106 | 106 | 135 |
| Operating profit | 6 | 7 | 9 | 17 | 22 | 25 | 28 | 32 |
| OPM % | 7% | 8% | 8% | 15% | 18% | 19% | 21% | 19% |
| Other income | 0 | 0 | 1 | 1 | 1 | 2 | -0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Depreciation | 7 | 7 | 7 | 9 | 9 | 9 | 10 | 11 |
| Profit before tax | -1 | -0 | 2 | 9 | 14 | 18 | 17 | 21 |
| Tax % | -34% | -165% | 49% | 27% | 27% | 14% | 38% | 24% |
| Net profit | -1 | 0 | 1 | 7 | 10 | 15 | 10 | 16 |
| EPS (₹) | -0.28 | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 | 4.41 | 6.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Tatva Chintan Pharma Chem Ltd annual results
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 136 | 206 | 263 | 300 | 434 | 424 | 394 | 383 | 506 | 556 |
| Operating profit | 23 | 34 | 55 | 67 | 109 | 61 | 69 | 35 | 94 | 108 |
| OPM % | 17% | 17% | 21% | 22% | 25% | 14% | 17% | 9% | 18% | 19% |
| Net profit | 12 | 21 | 38 | 52 | 96 | 45 | 30 | 6 | 42 | 51 |
| EPS (₹) | 15.30 | 25.56 | 47.03 | 26.02 | 43.25 | 20.52 | 12.97 | 2.44 | 17.98 | 21.97 |
TTM is the trailing twelve months to the most recent quarter.
Tatva Chintan Pharma Chem Ltd balance sheet
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 20 | 22 | 22 | 23 | 23 | 23 |
| Reserves | 51 | 72 | 110 | 146 | 451 | 493 | 714 | 715 | 758 |
| Borrowings | 56 | 77 | 91 | 90 | 120 | 170 | 14 | 36 | 120 |
| Other liabilities | 28 | 31 | 41 | 59 | 65 | 74 | 67 | 61 | 102 |
| Total liabilities | 144 | 188 | 249 | 315 | 658 | 759 | 819 | 836 | 1,004 |
| Fixed assets | 57 | 67 | 111 | 120 | 160 | 196 | 427 | 529 | 609 |
| CWIP | 10 | 6 | 5 | 10 | 51 | 231 | 77 | 24 | 25 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 4 |
| Other assets | 76 | 115 | 133 | 185 | 447 | 332 | 305 | 283 | 365 |
| Total assets | 144 | 188 | 249 | 315 | 658 | 759 | 819 | 836 | 1,004 |
As reported by the company. Total assets equal total liabilities by construction.
Tatva Chintan Pharma Chem Ltd cash flow
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 13 | 7 | 25 | 20 | 20 | 28 | 98 | 25 | 31 |
| Cash from investing | -30 | -17 | -40 | -21 | -197 | -101 | -121 | -65 | -116 |
| Cash from financing | 7 | 17 | 10 | -5 | 235 | 38 | 31 | 17 | 79 |
| Net cash flow | -10 | 8 | -5 | -6 | 59 | -36 | 8 | -24 | -6 |
| Free cash flow | -18 | -2 | -23 | -1 | -69 | -175 | -30 | -51 | -82 |
| CFO / operating profit | 105% | 39% | 61% | 44% | 36% | 61% | 157% | 85% | 42% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Tatva Chintan Pharma Chem Ltd operating ratios
| Per year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 22% | 28% | 28% | 26% | 9% | 7% | 1% | 7% |
| Debtor days | 77 | 73 | 69 | 110 | 48 | 73 | 65 | 85 | 86 |
| Inventory days | 148 | 114 | 175 | 173 | 319 | 262 | 320 | 246 | 319 |
| Days payable | 127 | 71 | 87 | 114 | 83 | 52 | 94 | 60 | 95 |
| Cash conversion cycle | 99 | 116 | 157 | 169 | 283 | 283 | 291 | 271 | 310 |
| Working capital days | 15 | 46 | 47 | 74 | 74 | 25 | 158 | 148 | 92 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Tatva Chintan Pharma Chem Ltd shareholding pattern
Promoters held 72.02% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.93% and DIIs 3.11%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| FIIs | 3.33% | 3.36% | 3.30% | 3.26% | 3.40% | 4.17% | 3.81% | 3.93% |
| DIIs | 6.83% | 6.34% | 5.46% | 5.11% | 3.87% | 3.32% | 2.99% | 3.11% |
| Public | 17.81% | 18.27% | 19.21% | 19.60% | 20.72% | 20.49% | 21.16% | 20.94% |
| No. of shareholders | 79,623 | 79,009 | 78,393 | 76,792 | 73,331 | 68,657 | 66,842 | 64,921 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Tatva Chintan Pharma Chem Ltd corporate filings
- Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Tatva Chintan Pharma Chem Limited Announces Successful Conclusion of 30th Annual General Meeting and Shareholder Approval of Key ResolutionsAGM/EGMlow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has successfully concluded its 30th Annual General…
Read the full analysis - Tatva Chintan Pharma Chem Limited concludes 30th AGM; seeks approval for increased borrowing limits and leadership re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has concluded its 30th Annual General Meeting, where…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Tatva Chintan Pharma Chem Ltd schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has issued an intimation regarding a scheduled meeting with…
Read the full analysis - Tatva Chintan Pharma Chem Ltd schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has issued an intimation regarding a scheduled meeting with…
Read the full analysis - Tatva Chintan Pharma Chem Limited receives credit rating upgrade from CRISIL to A-/StableCompany Updatemedium impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has received a credit rating upgrade from CRISIL…
Read the full analysis - Tatva Chintan Pharma Chem Ltd: Newspaper Publication of Statutory DisclosuresCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has published a newspaper advertisement in compliance with…
Read the full analysis - Tatva Chintan Pharma Chem Ltd announces record date and book closure for corporate actionsCorp. Actionlow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has issued a formal intimation regarding the record date…
Read the full analysis - Tatva Chintan Pharma Chem Ltd submits Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has submitted its Business Responsibility and…
Read the full analysis - Tatva Chintan Pharma Chem Limited Announces 30th Annual General Meeting and Submits FY 2025-26 Annual ReportOtherslow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has submitted its Annual Report for FY 2025-26 and…
Read the full analysis - Tatva Chintan Pharma Chem Limited Announces 30th AGM, Re-appointment of Key Management, and Increase in Borrowing LimitsAGM/EGMmedium impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has issued a notice for its 30th Annual General Meeting…
Read the full analysis - Tatva Chintan Pharma Chem Limited announces resignation of Assistant Vice President - Research and DevelopmentCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has formally disclosed the resignation of Mr. Ajay…
Read the full analysis - Tatva Chintan Pharma Chem Ltd: Routine Newspaper Publication of Financial/Corporate DisclosuresCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has published a mandatory newspaper advertisement in…
Read the full analysis - Tatva Chintan Pharma Chem Limited issues tax deduction (TDS) communication for FY 2025-26 final dividendCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Limited has issued a formal communication to shareholders…
Read the full analysis - Tatva Chintan Pharma Chem Ltd schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has announced an upcoming meeting with analysts and…
Read the full analysis - Tatva Chintan Pharma Chem Ltd schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Tatva Chintan Pharma Chem Ltd has issued an intimation regarding a scheduled meeting with…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.